|Awarded On||February 21, 2018|
|Title||Evidence-Based Hepatocellular Cancer Prevention through Targeted Hepatitis C Screening and Navigation|
|Award Mechanism||Evidence-Based Prevention Programs and Services|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Mamta Jain|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
The most common primary liver cancer is hepatocellular carcinoma (HCC). Estimates of highest incidence in the US are known to be in areas with elevated prevalence for hepatitis C virus (HCV) infection. Therefore, early detection and treatment of HCV will support HCC prevention for which hepatitis C infection is the main risk factor.
Texas maintains the 2nd highest incidence rate for HCC in the nation at 9.1/100,000 persons and HCC is the fastest growing cancer in the state. Of the 3,031 cases that occurred in Texas in 2015, nearly 8% will occur in Tarrant County and surrounding areas–the project service area. Barriers to addressing HCV and associated HCC include knowledge gaps at both...